882679-90-5

Basic information

• Product Name: 5-CHLORO-2-FLUORONICOTINALDEHYDE
• Synonyms: 5-CHLORO-2-FLUORO-3-FORMYLPYRIDINE;5-CHLORO-2-FLUORONICOTINALDEHYDE;5-chloro-2-fluoro-pyridine-3-carbaldehyde
• CAS NO: 882679-90-5
• Molecular Formula: C6H3ClFNO
• Molecular Weight: 159.55
• Product Categories: Heterocyclic Compounds;Boronic Acid;Heterocycles;Intermediates & Fine Chemicals;Nicotine Derivatives;Pharmaceuticals
• Mol File: 882679-90-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 238℃
• Flash Point: 98℃
• Appearance: /
• Density: 1.444
• Vapor Pressure: 0.043mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 5-CHLORO-2-FLUORONICOTINALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-2-FLUORONICOTINALDEHYDE(882679-90-5)
• EPA Substance Registry System: 5-CHLORO-2-FLUORONICOTINALDEHYDE(882679-90-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 882679-90-5(Hazardous Substances Data)

Usage

Uses

5-Chloro-2-fluoropyridine-3-carboxaldehyde can be used in the preparation of trisubstituted amine compounds as CETP inhibitors useful in the treatment of arteriosclerotic diseases, hyperlipemia, dyslipidemia and related diseases.

InChI:InChI=1/C6H3ClFNO/c7-5-1-4(3-10)6(8)9-2-5/h1-3H

Upstream product

• 4394-85-8 4-morpholinecarboxaldehyde 
• 1480-65-5 2-fluoro-5-chloropyridine 

Downstream Products

• 1119718-20-5 5-chloro-3-(difluoromethyl)-2-fluoropyridine 

Relevant articles and documents

BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT， AMELIORATION OR PREVENTION OF INFLUENZA

The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing influenza.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.